Novo Nordisk has told the world it expects patients to lose “at least 25%” of their body weight on its experimental drug CagriSema. On Friday, Novo released the results of a large Phase 3 trial of the ...

Wall Street was poised to open with significant losses on Friday as the possibility of government shutdown right before ...

Eli Lilly said the FDA approved Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity, the first and only prescription medicine for those suffering from this condition.

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 471.82% and ...

This advisor isn’t losing any sleep over the markets. In fact, looking back at 2024 and forward into 2025, there are some ...

The US Food and Drug Administration on Friday approved the first prescription medicine for obstructive sleep apnea: the ...

The Ozempic maker's stock tanked after its highly anticipated CagriSema drug trial showed an average of 22.7% weight loss, ...

J.P. Morgan’s U.S. equity analysts picked their top stocks for 2025 in healthcare, selecting “the most compelling investment ...

As Novo Nordisk and Eli Lilly expand sales of their popular diabetes and weight-loss drugs, cheaper copies of their patented ...

Eli Lilly’s Kisunla Approved in China, Paving the Way for Innovative Alzheimer’s Treatment Options Elon Musk Lights Up Tesla Buzz with $690.42 Price Target and $2 Trillion Market Cap Forecast ...

As Novo Nordisk and Eli Lilly expand sales of their popular diabetes and weight-loss drugs, cheaper copies of their patented ...